Current Report Filing (8-k)
February 26 2014 - 5:25PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR
15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) |
February 24, 2014 |
NANOVIRICIDES, INC. |
(Exact Name of Registrant as Specified in Its Charter) |
Nevada |
000-1379006 |
76-0674577 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
|
|
|
135 Wood Street, Suite 205
West Haven, Connecticut |
06516 |
(Address of Principal Executive Offices) |
(Zip Code) |
(203) 937-6137 |
(Registrant’s Telephone Number, Including Area Code) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
From February 18, 2014 to February
20, 2014, the Registrant’s President and Chairman Dr. Anil Diwan purchased an aggregate of 50,000 shares of the
Registrant’s common stock, par value $0.001 per share (the “Common Stock”) in open market transactions. On
February 25, 2014, Dr. Diwan repaid $83,900 to the Company as a result of the “short term profits” accrued from
the sale of Common Stock at a higher price and the later purchase at a lower price.
Dr. Diwan originally purchased certain
shares of Common Stock in February, 2013. Subsequently, Dr. Diwan sold a portion of these shares as reported on October 21, 2013.
Dr. Diwan purchased 50,000 shares of Common Stock, as reported on a Form 4 filed with the Securities and Exchange Commission on
February 24, 2014. Since this repurchase fell within the limitations of Section 16(b) of the Securities and Exchange Act of 1934,
which relates to “short term sales” by “insiders” of a public company, Dr. Diwan disgorged the resulting
net profits of $83,900 on February 25, 2014.
| Item 9.01 | Financial Statement and Exhibits. |
| 99.1 | Press Release dated February
26, 2014 |
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE
SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO
DULY AUTHORIZED.
|
NANOVIRICIDES, INC. |
|
|
|
|
|
|
|
|
|
Date: February 26, 2014 |
By: |
/s/ Eugene Seymour, MD |
|
|
Name: Eugene Seymour
Title: Chief Executive Officer |
|
INDEX
OF EXHIBITS
Exhibit Number |
|
Description |
|
|
|
99.1 |
|
Press Release February 26, 2014 |
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jul 2023 to Jul 2024